Specgx Llc Company Profile
What is the competitive landscape for SPECGX LLC
SPECGX LLC has sixty-four approved drugs.
Drugs and US Patents for Specgx Llc
Expired US Patents for Specgx Llc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Specgx Llc | RESTORIL | temazepam | CAPSULE;ORAL | 018163-003 | Oct 25, 1991 | 5,326,758 | ⤷ Start Trial |
| Specgx Llc | PAMELOR | nortriptyline hydrochloride | CAPSULE;ORAL | 018013-001 | Approved Prior to Jan 1, 1982 | 3,922,305 | ⤷ Start Trial |
| Specgx Llc | PAMELOR | nortriptyline hydrochloride | CAPSULE;ORAL | 018013-003 | Approved Prior to Jan 1, 1982 | 3,922,305 | ⤷ Start Trial |
| Specgx Llc | EXALGO | hydromorphone hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 021217-003 | Mar 1, 2010 | 5,914,131 | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for SPECGX LLC drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Oral Solution | 5 mg/5 mL and 10 mg/5 mL | ➤ Subscribe | 2010-04-13 |
Similar Applicant Names
Here is a list of applicants with similar names.

